{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:29Z","timestamp":1792788329577,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04275-y","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T07:57:22Z","timestamp":1748505442000},"page":"356-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A practical use of bone turnover markers in management of patients with skeletal fragility"],"prefix":"10.1007","volume":"89","author":[{"given":"Alessandro","family":"Brunetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia Maria Silvana","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Birtolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Vescini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Gerardo","family":"Lania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gherardo","family":"Mazziotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"1","key":"4275_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"J.A. Kanis et al., European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 30(1), 3\u201344 (2019).","journal-title":"Osteoporos. Int."},{"issue":"7","key":"4275_CR2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s40618-023-02056-w","volume":"46","author":"L Cianferotti","year":"2023","unstructured":"L. Cianferotti et al., Bone quality in endocrine diseases: determinants and clinical relevance. J. Endocrinol. Invest. 46(7), 1283\u20131304 (2023).","journal-title":"J. Endocrinol. Invest."},{"key":"4275_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/bonekey.2013.215","volume":"3","author":"NA Sims","year":"2014","unstructured":"N.A. Sims, T.J. Martin, Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep. 3, 481 (2014).","journal-title":"Bonekey Rep."},{"issue":"8","key":"4275_CR4","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","volume":"49","author":"S Vasikaran","year":"2011","unstructured":"S. Vasikaran et al., International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin. Chem. Lab. Med. 49(8), 1271\u20131274 (2011).","journal-title":"Clin. Chem. Lab. Med."},{"issue":"3","key":"4275_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/endrev\/bnac031","volume":"44","author":"M Schini","year":"2023","unstructured":"M. Schini et al., Bone turnover markers: basic biology to clinical applications. Endocr. Rev. 44(3), 417\u2013473 (2023).","journal-title":"Endocr. Rev."},{"issue":"Pt 5","key":"4275_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1258\/acb.2011.011040","volume":"48","author":"L Marin","year":"2011","unstructured":"L. Marin et al., Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases. Ann. Clin. Biochem. 48(Pt 5), 447\u2013451 (2011).","journal-title":"Ann. Clin. Biochem."},{"issue":"Pt 1","key":"4275_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1258\/acb.2009.009110","volume":"47","author":"MK Koivula","year":"2010","unstructured":"M.K. Koivula et al., Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide. Ann. Clin. Biochem. 47(Pt 1), 67\u201371 (2010).","journal-title":"Ann. Clin. Biochem."},{"issue":"4","key":"4275_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0009-9120(87)80002-4","volume":"20","author":"DW Moss","year":"1987","unstructured":"D.W. Moss, Diagnostic aspects of alkaline phosphatase and its isoenzymes. Clin. Biochem. 20(4), 225\u2013230 (1987).","journal-title":"Clin. Biochem."},{"key":"4275_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cca.2019.11.012","volume":"501","author":"A Nizet","year":"2020","unstructured":"A. Nizet et al., Bone alkaline phosphatase: an important biomarker in chronic kidney disease - mineral and bone disorder. Clin. Chim. Acta 501, 198\u2013206 (2020).","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"4275_CR10","first-page":"439","volume":"15","author":"MP Whyte","year":"1994","unstructured":"M.P. Whyte, Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr. Rev. 15(4), 439\u2013461 (1994).","journal-title":"Endocr. Rev."},{"issue":"Pt 4","key":"4275_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1177\/000456320003700402","volume":"37","author":"AJ Lee","year":"2000","unstructured":"A.J. Lee, S. Hodges, R. Eastell, Measurement of osteocalcin. Ann. Clin. Biochem. 37(Pt 4), 432\u2013446 (2000).","journal-title":"Ann. Clin. Biochem."},{"issue":"3","key":"4275_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1359\/jbmr.1997.12.3.447","volume":"12","author":"R Baumgrass","year":"1997","unstructured":"R. Baumgrass, M.K. Williamson, P.A. Price, Identification of peptide fragments generated by digestion of bovine and human osteocalcin with the lysosomal proteinases cathepsin B, D, L, H, and S. J. Bone Min. Res. 12(3), 447\u2013455 (1997).","journal-title":"J. Bone Min. Res."},{"issue":"Pt 3","key":"4275_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1042\/bj3450473","volume":"345","author":"PA Cloos","year":"2000","unstructured":"P.A. Cloos, C. Fledelius, Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem. J. 345(Pt 3), 473\u2013480 (2000).","journal-title":"Biochem. J."},{"issue":"4","key":"4275_CR14","first-page":"97","volume":"26","author":"MJ Seibel","year":"2005","unstructured":"M.J. Seibel, Biochemical markers of bone turnover: part I: biochemistry and variability. Clin. Biochem. Rev. 26(4), 97\u2013122 (2005).","journal-title":"Clin. Biochem. Rev."},{"issue":"3","key":"4275_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00198-012-2097-4","volume":"24","author":"I Baxter","year":"2013","unstructured":"I. Baxter et al., Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice. Osteoporos. Int. 24(3), 941\u2013947 (2013).","journal-title":"Osteoporos. Int."},{"issue":"1","key":"4275_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bone.2003.04.002","volume":"34","author":"RA Hannon","year":"2004","unstructured":"R.A. Hannon et al., Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34(1), 187\u2013194 (2004).","journal-title":"Bone"},{"issue":"8","key":"4275_CR17","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00198-020-05362-8","volume":"31","author":"E Cavalier","year":"2020","unstructured":"E. Cavalier et al., European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of beta-isomerized C-terminal telopeptide of type I collagen (beta-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism. Osteoporos. Int. 31(8), 1461\u20131470 (2020).","journal-title":"Osteoporos. Int."},{"issue":"2","key":"4275_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1359\/jbmr.2001.16.2.371","volume":"16","author":"D Hunter","year":"2001","unstructured":"D. Hunter et al., Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J. Bone Min. Res. 16(2), 371\u2013378 (2001).","journal-title":"J. Bone Min. Res."},{"issue":"4","key":"4275_CR19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1210\/jcem-72-4-808","volume":"72","author":"PJ Kelly","year":"1991","unstructured":"P.J. Kelly et al., Genetic factors in bone turnover. J. Clin. Endocrinol. Metab. 72(4), 808\u2013813 (1991).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4275_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-2265.2009.03606.x","volume":"72","author":"JS Walsh","year":"2010","unstructured":"J.S. Walsh et al., Hormonal determinants of bone turnover before and after attainment of peak bone mass. Clin. Endocrinol. 72(3), 320\u2013327 (2010).","journal-title":"Clin. Endocrinol."},{"issue":"4 Pt 1","key":"4275_CR21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/gme.0b013e31815f8917","volume":"15","author":"ML Gass","year":"2008","unstructured":"M.L. Gass et al., Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Menopause 15(4 Pt 1), 667\u2013675 (2008).","journal-title":"Menopause"},{"issue":"4","key":"4275_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00774-013-0430-4","volume":"31","author":"B Mozzanega","year":"2013","unstructured":"B. Mozzanega et al., Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle. J. Bone Min. Metab. 31(4), 461\u2013467 (2013).","journal-title":"J. Bone Min. Metab."},{"issue":"7","key":"4275_CR23","first-page":"2266","volume":"83","author":"S Khosla","year":"1998","unstructured":"S. Khosla et al., Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 83(7), 2266\u20132274 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"4275_CR24","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1210\/jc.2016-1183","volume":"101","author":"J Redmond","year":"2016","unstructured":"J. Redmond et al., Diurnal Rhythms of Bone Turnover Markers in Three Ethnic Groups. J. Clin. Endocrinol. Metab. 101(8), 3222\u20133230 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4275_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S8756-3282(01)00662-7","volume":"30","author":"NH Bjarnason","year":"2002","unstructured":"N.H. Bjarnason et al., Mechanism of circadian variation in bone resorption. Bone 30(1), 307\u2013313 (2002).","journal-title":"Bone"},{"issue":"2","key":"4275_CR26","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1359\/JBMR.051014","volume":"21","author":"JS Chen","year":"2006","unstructured":"J.S. Chen et al., Effect of age-related chronic immobility on markers of bone turnover. J. Bone Min. Res. 21(2), 324\u2013331 (2006).","journal-title":"J. Bone Min. Res."},{"issue":"10","key":"4275_CR27","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1210\/jc.2011-3361","volume":"97","author":"MS Ardawi","year":"2012","unstructured":"M.S. Ardawi, A.A. Rouzi, M.H. Qari, Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J. Clin. Endocrinol. Metab. 97(10), 3691\u20133699 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4275_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00198-016-3759-4","volume":"28","author":"HJ Wen","year":"2017","unstructured":"H.J. Wen et al., Effects of short-term step aerobics exercise on bone metabolism and functional fitness in postmenopausal women with low bone mass. Osteoporos. Int. 28(2), 539\u2013547 (2017).","journal-title":"Osteoporos. Int."},{"issue":"2","key":"4275_CR29","first-page":"e21","volume":"1","author":"S Ikegami","year":"2009","unstructured":"S. Ikegami et al., Comparison in bone turnover markers during early healing of femoral neck fracture and trochanteric fracture in elderly patients. Orthop. Rev. 1(2), e21 (2009).","journal-title":"Orthop. Rev."},{"issue":"3","key":"4275_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1302\/0301-620X.92B3.22787","volume":"92","author":"G Cox","year":"2010","unstructured":"G. Cox et al., Bone-turnover markers in fracture healing. J. Bone Jt. Surg. Br. 92(3), 329\u2013334 (2010).","journal-title":"J. Bone Jt. Surg. Br."},{"issue":"7","key":"4275_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1046\/j.1532-5415.2001.49177.x","volume":"49","author":"JA Yu-Yahiro","year":"2001","unstructured":"J.A. Yu-Yahiro et al., Serum and urine markers of bone metabolism during the year after hip fracture. J. Am. Geriatr. Soc. 49(7), 877\u2013883 (2001).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"3","key":"4275_CR32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00774-003-0476-9","volume":"22","author":"L Alvarez","year":"2004","unstructured":"L. Alvarez et al., Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. J. Bone Min. Metab. 22(3), 254\u2013259 (2004).","journal-title":"J. Bone Min. Metab."},{"issue":"4","key":"4275_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/MED.0000000000000869","volume":"31","author":"P Brouwers","year":"2024","unstructured":"P. Brouwers, A. Bouquegneau, E. Cavalier, Insight into the potential of bone turnover biomarkers: integration in the management of osteoporosis and chronic kidney disease-associated osteoporosis. Curr. Opin. Endocrinol. Diabetes Obes. 31(4), 149\u2013156 (2024).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"4275_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinbiochem.2022.09.002","volume":"109-110","author":"JP Brown","year":"2022","unstructured":"J.P. Brown et al., Current use of bone turnover markers in the management of osteoporosis. Clin. Biochem. 109-110, 1\u201310 (2022).","journal-title":"Clin. Biochem."},{"issue":"5","key":"4275_CR35","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/00045632211025567","volume":"58","author":"A Tridimas","year":"2021","unstructured":"A. Tridimas, A. Milan, E. Marks, Assessing bone formation in patients with chronic kidney disease using procollagen type I N-terminal propeptide (PINP): The choice of assay makes a difference. Ann. Clin. Biochem. 58(5), 528\u2013536 (2021).","journal-title":"Ann. Clin. Biochem."},{"issue":"4","key":"4275_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/er.2018-00005","volume":"39","author":"G Mazziotti","year":"2018","unstructured":"G. Mazziotti, S. Frara, A. Giustina, Pituitary Diseases and Bone. Endocr. Rev. 39(4), 440\u2013488 (2018).","journal-title":"Endocr. Rev."},{"issue":"11","key":"4275_CR37","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","volume":"5","author":"R Eastell","year":"2017","unstructured":"R. Eastell, P. Szulc, Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 5(11), 908\u2013923 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"4275_CR38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","volume":"94","author":"H Johansson","year":"2014","unstructured":"H. Johansson et al., A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif. Tissue Int. 94(5), 560\u2013567 (2014).","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"4275_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13018-019-1100-6","volume":"14","author":"A Tian","year":"2019","unstructured":"A. Tian et al., Reference markers of bone turnover for prediction of fracture: a meta-analysis. J. Orthop. Surg. Res. 14(1), 68 (2019).","journal-title":"J. Orthop. Surg. Res."},{"issue":"10","key":"4275_CR40","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s12325-019-01063-9","volume":"36","author":"M Lorentzon","year":"2019","unstructured":"M. Lorentzon et al., Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv. Ther. 36(10), 2811\u20132824 (2019).","journal-title":"Adv. Ther."},{"issue":"3","key":"4275_CR41","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","volume":"28","author":"A Diez-Perez","year":"2017","unstructured":"A. Diez-Perez et al., International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos. Int. 28(3), 767\u2013774 (2017).","journal-title":"Osteoporos. Int."},{"issue":"3","key":"4275_CR42","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"R. Eastell et al., Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J. Bone Min. Res. 26(3), 530\u2013537 (2011).","journal-title":"J. Bone Min. Res."},{"issue":"2","key":"4275_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00198-011-1583-4","volume":"23","author":"P Hadji","year":"2012","unstructured":"P. Hadji et al., Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos. Int. 23(2), 625\u2013633 (2012).","journal-title":"Osteoporos. Int."},{"issue":"9886","key":"4275_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","volume":"382","author":"JN Tsai","year":"2013","unstructured":"J.N. Tsai et al., Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382(9886), 50\u201356 (2013).","journal-title":"Lancet"},{"issue":"4","key":"4275_CR45","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.bone.2010.12.006","volume":"48","author":"M Tsujimoto","year":"2011","unstructured":"M. Tsujimoto et al., PINP as an aid for monitoring patients treated with teriparatide. Bone 48(4), 798\u2013803 (2011).","journal-title":"Bone"},{"issue":"6","key":"4275_CR46","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00774-023-01455-6","volume":"41","author":"T Matsumoto","year":"2023","unstructured":"T. Matsumoto et al., Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study. J. Bone Min. Metab. 41(6), 807\u2013816 (2023).","journal-title":"J. Bone Min. Metab."},{"issue":"16","key":"4275_CR47","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"F. Cosman et al., Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N. Engl. J. Med. 375(16), 1532\u20131543 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4275_CR48","doi-asserted-by":"publisher","first-page":"115336","DOI":"10.1016\/j.bone.2020.115336","volume":"136","author":"A Fontalis","year":"2020","unstructured":"A. Fontalis, R. Eastell, The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone 136, 115336 (2020).","journal-title":"Bone"},{"issue":"1","key":"4275_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/clinchem\/29.1.25","volume":"29","author":"EK Harris","year":"1983","unstructured":"E.K. Harris, T. Yasaka, On the calculation of a \u201creference change\u201d for comparing two consecutive measurements. Clin. Chem. 29(1), 25\u201330 (1983).","journal-title":"Clin. Chem."},{"issue":"1","key":"4275_CR50","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/EJE-17-0585","volume":"178","author":"R Eastell","year":"2018","unstructured":"R. Eastell et al., DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?. Eur. J. Endocrinol. 178(1), R19\u2013R31 (2018).","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"4275_CR51","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1185\/030079905X75096","volume":"22","author":"R Eastell","year":"2006","unstructured":"R. Eastell et al., Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr. Med. Res. Opin. 22(1), 61\u201366 (2006).","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"4275_CR52","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1359\/jbmr.080703","volume":"24","author":"SJ Glover","year":"2009","unstructured":"S.J. Glover et al., Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J. Bone Min. Res. 24(3), 389\u2013397 (2009).","journal-title":"J. Bone Min. Res."},{"issue":"5","key":"4275_CR53","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.bone.2012.02.003","volume":"50","author":"R Eastell","year":"2012","unstructured":"R. Eastell et al., Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study. Bone 50(5), 1141\u20131147 (2012).","journal-title":"Bone"},{"issue":"5","key":"4275_CR54","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00223-008-9126-5","volume":"82","author":"S Adami","year":"2008","unstructured":"S. Adami et al., Determinants of bone turnover markers in healthy premenopausal women. Calcif. Tissue Int. 82(5), 341\u2013347 (2008).","journal-title":"Calcif. Tissue Int."},{"issue":"10","key":"4275_CR55","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"F. Cosman et al., Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis. Osteoporos. Int. 25(10), 2359\u20132381 (2014).","journal-title":"Osteoporos. Int."},{"issue":"1","key":"4275_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"R.A. Adler et al., Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the american society for bone and mineral research. J. Bone Min. Res. 31(1), 16\u201335 (2016).","journal-title":"J. Bone Min. Res."},{"key":"4275_CR57","doi-asserted-by":"crossref","unstructured":"V.Z. Borba et al. Bone turnover 18 months after a single intravenous dose of zoledronic acid. Int. J. Clin. Pract. 61(6), 1058\u20131062 (2007)","DOI":"10.1111\/j.1742-1241.2007.01392.x"},{"issue":"8","key":"4275_CR58","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/jbmr.1644","volume":"27","author":"RM Jacques","year":"2012","unstructured":"R.M. Jacques et al., Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Min. Res. 27(8), 1627\u20131634 (2012).","journal-title":"J. Bone Min. Res."},{"issue":"4","key":"4275_CR59","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00198-018-04823-5","volume":"30","author":"KE Naylor","year":"2019","unstructured":"K.E. Naylor et al., Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis. Osteoporos. Int. 30(4), 917\u2013922 (2019).","journal-title":"Osteoporos. Int."},{"issue":"7","key":"4275_CR60","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","volume":"174","author":"DC Bauer","year":"2014","unstructured":"D.C. Bauer et al., Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern. Med. 174(7), 1126\u20131134 (2014).","journal-title":"JAMA Intern. Med."},{"issue":"5","key":"4275_CR61","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/jbmr.1570","volume":"27","author":"S Boonen","year":"2012","unstructured":"S. Boonen et al., Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk\u2013a perspective. J. Bone Min. Res. 27(5), 963\u2013974 (2012).","journal-title":"J. Bone Min. Res."},{"key":"4275_CR62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"E. Tsourdi et al., Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone 105, 11\u201317 (2017).","journal-title":"Bone"},{"issue":"2","key":"4275_CR63","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"S.R. Cummings et al., Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Min. Res. 33(2), 190\u2013198 (2018).","journal-title":"J. Bone Min. Res."},{"issue":"4","key":"4275_CR64","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"H.G. Bone et al., Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96(4), 972\u2013980 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4275_CR65","unstructured":"E. Tsourdi et al., Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 26, dgaa756 (2020)."},{"issue":"9999","key":"4275_CR66","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"B.Z. Leder et al., Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386(9999), 1147\u20131155 (2015).","journal-title":"Lancet"},{"issue":"7","key":"4275_CR67","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS Solling","year":"2021","unstructured":"A.S. Solling, T. Harslof, B. Langdahl, Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study. J. Bone Min. Res. 36(7), 1245\u20131254 (2021).","journal-title":"J. Bone Min. Res."},{"issue":"4","key":"4275_CR68","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jbmr\/zjae023","volume":"39","author":"AS Kim","year":"2024","unstructured":"A.S. Kim et al., Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition. J. Bone Min. Res. 39(4), 484\u2013497 (2024).","journal-title":"J. Bone Min. Res."},{"key":"4275_CR69","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40618-025-02542-3","volume":"48","author":"A Piasentier","year":"2025","unstructured":"A. Piasentier et al., Early administration of romosozumab prevents rebound of bone resorption related to denosumab withdrawal in fractured post-menopausal women: a real-world prospective study. J. Endocrinol. Invest. 48, 1249\u20131256 (2025).","journal-title":"J. Endocrinol. Invest."},{"issue":"1","key":"4275_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes, C.K.D.M.B.D.U.W.G.","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes, C.K.D.M.B.D.U.W.G., KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 7(1), 1\u201359 (2017). p.","journal-title":"Kidney Int. Suppl."},{"key":"4275_CR71","doi-asserted-by":"crossref","unstructured":"H.P. Bhattoa et al., Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Osteoporos. Int 36(4), 579\u2013608 (2025).","DOI":"10.1007\/s00198-025-07422-3"},{"issue":"8","key":"4275_CR72","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/ndt\/gfu055","volume":"29","author":"Y Maruyama","year":"2014","unstructured":"Y. Maruyama et al., A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. Nephrol. Dial. Transpl. 29(8), 1532\u20131538 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"issue":"4","key":"4275_CR73","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ekir.2024.01.002","volume":"9","author":"S Yamamoto","year":"2024","unstructured":"S. Yamamoto et al., Alkaline Phosphatase and Parathyroid Hormone Levels: International Variation and Associations With Clinical Outcomes in the DOPPS. Kidney Int. Rep. 9(4), 863\u2013876 (2024).","journal-title":"Kidney Int. Rep."},{"issue":"1","key":"4275_CR74","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfr317","volume":"27","author":"S Iimori","year":"2012","unstructured":"S. Iimori et al., Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients\u2013a single-center cohort study. Nephrol. Dial. Transpl. 27(1), 345\u2013351 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"issue":"4","key":"4275_CR75","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s00774-022-01331-9","volume":"40","author":"A Horikawa","year":"2022","unstructured":"A. Horikawa et al., The relationship between chronic kidney disease and denosumab-induced hypocalcemia in high-age osteoporotic patients. J. Bone Min. Metab. 40(4), 670\u2013676 (2022).","journal-title":"J. Bone Min. Metab."},{"issue":"10","key":"4275_CR76","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00198-015-3188-9","volume":"26","author":"L Masi","year":"2015","unstructured":"L. Masi et al., Taxonomy of rare genetic metabolic bone disorders. Osteoporos. Int. 26(10), 2529\u20132558 (2015).","journal-title":"Osteoporos. Int."},{"issue":"1","key":"4275_CR77","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00223-024-01323-z","volume":"116","author":"F Alsarraf","year":"2025","unstructured":"F. Alsarraf, D.S. Ali, M.L. Brandi, The use of bone biomarkers, imaging tools, and genetic tests in the diagnosis of rare bone disorders. Calcif. Tissue Int. 116(1), 32 (2025).","journal-title":"Calcif. Tissue Int."},{"issue":"3","key":"4275_CR78","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00198-023-06844-1","volume":"35","author":"AA Khan","year":"2024","unstructured":"A.A. Khan et al., Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. Osteoporos. Int. 35(3), 431\u2013438 (2024).","journal-title":"Osteoporos. Int."},{"issue":"4","key":"4275_CR79","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/jbmr.3657","volume":"34","author":"SH Ralston","year":"2019","unstructured":"S.H. Ralston et al., Diagnosis and management of paget\u2019s disease of bone in adults: a clinical guideline. J. Bone Min. Res. 34(4), 579\u2013604 (2019).","journal-title":"J. Bone Min. Res."},{"issue":"6","key":"4275_CR80","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40618-024-02318-1","volume":"47","author":"D Rendina","year":"2024","unstructured":"D. Rendina et al., Diagnosis and treatment of Paget\u2019s disease of bone: position paper from the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS). J. Endocrinol. Invest. 47(6), 1335\u20131360 (2024).","journal-title":"J. Endocrinol. Invest."},{"issue":"5","key":"4275_CR81","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00223-019-00522-3","volume":"104","author":"L Gennari","year":"2019","unstructured":"L. Gennari et al., Paget\u2019s disease of bone. Calcif. Tissue Int. 104(5), 483\u2013500 (2019).","journal-title":"Calcif. Tissue Int."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04275-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04275-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04275-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:24:04Z","timestamp":1757179444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04275-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":81,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4275"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04275-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G.M. received fees for educational purposes from Amgen\/UCB and Sanofi and lecture fees from Theramex and UCB, outside the submitted work. A.G.L. received grants from Pfizer and lecture fees from Recordati, outside the submitted work. F.V. received fees for educational purposes from IBSA and lecture fees from Theramex, Amgen, Bruno farmaceutici, IBSA, UCB, outside the submitted work. The other authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval is not required for this review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}